Related Experiment Video

Updated: Jul 11, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Medical resource use and costs of congestive heart failure after carvedilol use

Mohammad M Najib1, Renée J Goldberg Arnold, Diana J Kaniecki

  • 1Health Care Research and New Business Development, Pharmacon International, New York, New York 10018, USA. mnajib@pharmacon.com

Heart Disease (Hagerstown, Md.)
|April 27, 2002
PubMed

Insights

Carvedilol significantly reduces healthcare costs and utilization for congestive heart failure patients. This study found lower overall expenditures and fewer hospital admissions for patients treated with carvedilol.

Area of Science:

  • Cardiology
  • Health Economics
  • Pharmacoeconomics

Background:

  • Congestive heart failure (CHF) is a major cause of healthcare utilization and expenditure.
  • Carvedilol is a beta-blocker used in CHF management, but its economic impact requires further investigation.

Purpose of the Study:

  • To compare healthcare use and costs in congestive heart failure patients with and without carvedilol treatment.
  • To assess the economic impact of carvedilol in managing CHF.

Main Methods:

  • Retrospective cohort study using claims and medical chart data (1997-1999).
  • Inclusion criteria: adult patients with CHF diagnosis and continuous carvedilol treatment (≥4 months for cases).
  • Matching of case and control patients on demographics and concomitant medications; statistical analysis using ANOVA, chi-square, and multivariate models.

Main Results:

  • 128 carvedilol-treated patients (cases) and 147 control patients were identified with no significant demographic differences.
  • Carvedilol treatment was associated with a significant reduction in overall healthcare expenditures (approx. $14,530).
  • Carvedilol group showed lower facility expenditures (approx. $9,000), fewer hospital admissions, and shorter lengths of stay.

Conclusions:

  • Carvedilol treatment is associated with significantly reduced healthcare use and costs in congestive heart failure patients.
  • Carvedilol offers economic benefits in CHF management through decreased hospitalizations and overall expenditures.
  • These findings support the cost-effectiveness of carvedilol in CHF care.

More Related Videos

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease06:16

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...